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Streptococcus pneumoniae is the singlemost important cause
of acute purulent meningitis, occurring in 47% of cases of
acute bacterial meningitis.1 To the authors’ knowledge,
there are no published data on the treatment of pneumo-
coccal meningitis based on local epidemiological studies in
Turkey. In this letter we refer to recent and current pneu-
mococcal studies carried out in accordance with the National
Committee for Clinical Laboratory Standards. Only the sus-
ceptibility test results of pathogenic pneumococci are taken
into account; resistance patterns of those obtained from
carriers are excluded. The epidemiological data from which
the therapeutic options for pneumococcal meningitis are
derived are presented in Table 1.
Approximately 40% of pneumococci are now penicillin
resistant and in Turkey 20% of resistant isolates are high-
level penicillin resistant.2 For this reason penicillin is no
longer the best choice for the treatment of pneumococcal
meningitis.
Third generation cephalosporins (e.g. ceftriaxone or cefo-
taxime) are another possible therapeutic option when pneu-
mococcus is the probable cause of infection. Ten studies on
the susceptibility patterns of pathogenic pneumococci for
third generation cephalosporins have been carried out in
Turkey.3—6 Six of them, completed since 2000, reported
ceftriaxone and cefotaxime resistances not exceeding
2.3%.5,6 Moreover, in one study over the period 1998—
2000, all of the isolates were susceptible to cefepime.
Seventy-six penicillin-resistant pneumococci isolated
between 1997 and 2001 were evaluated in a reference
laboratory in Ankara.7 Only four of these isolates (5.3%) were
found to be cefotaxime-resistant. Consequently, third gen-
eration cephalosporins, ceftriaxone and cefotaxime in par-
ticular, are the antibacterial agents of choice in the
treatment of pneumococcal meningitis in Turkey.
Vancomycin resistance in pneumococci has not been
reported in Turkish studies.2 If a community is known to have
significant cephalosporin resistance (minimum inhibitory
concentration >0.5 mg/mL) in more than 3% of invasive
pneumococci, vancomycin should be added to the third-
generation cephalosporin.8,9 No recent Turkish studies show
resistance rates which exceed the probable threshold of 3%1201-9712/$32.00 # 2005 Published by Elsevier Ltd on behalf of Internfor additional vancomycin use. In our opinion, updating of
current data is required; empirical vancomycin administra-
tion in probable pneumococcal meningitis is unnecessary, but
its use in Turkey is not far off.
Two carbapenems, imipenem and meropenem, have been
extensively studied in patients with bacterial meningitis.
Unfortunately, carbapenem activity against pneumococci
has been little investigated in Turkey. A study published in
1996 mentions 2.2% resistance to imipenem and another
completed in 2000 shows no imipenem resistance.
The fluoroquinolones have undergone extensive study in
experimental animal models of penicillin-resistant pneu-
mococcal meningitis. Currently, the recommended quino-
lones in the treatment of acute bacterial meningitis are
gatifloxacin and moxifloxacin. Data derived from recent
local Turkish studies show no resistance to levofloxacin,
grepafloxacin, gemifloxacin and moxifloxacin.5,6,10 The
MIC90 of gemifloxacin was found to be 2-fold lower than
that of moxifloxacin and 32-fold lower than those of cipro-
floxacin and levofloxacin.5 According to these results,
newer fluoroquinolones would also appear to be acceptable
alternatives in the treatment of pneumococcal meningitis.
Moreover, newer fluoroquinolones act synergistically with
vancomycin and beta-lactam antibiotics against penicillin-
resistant pneumococcal meningitis in experimental rabbit
meningitis, potentially providing a new therapeutic strategy.
In one report the combination of ceftriaxonewith levofloxacin
and in another cefotaxime with levofloxacin, acted synergis-
tically in experimental pneumococcal meningitis and over-
came the risks of quinolone-induced resistance.11,12 Similarly,
meropenem combined with levofloxacin provided synergism
and sterilized the CSF in a rabbit model of pneumococcal
meningitis.13 Epidemiological data in Turkey would suggest
that these approaches must perhaps be spared for the future,
when extended spectrum cephalosporin resistance rates are
more elevated.
Chloramphenicol, which has been in use for a long time,
has been recommended for the treatment of acute bacterial
meningitis due to its relatively low cost, which makes it more
accessible to communities with limited resources. In recent
local Turkish studies, chloramphenicol resistance patterns
were found to be less than 10% and this drug, alone or in
combination, may be regarded as an alternative option.
Trimethoprim—sulfamethoxazole is one of the most evalu-
ated antibiotics in Turkey. Local research undertaken from
2000 on, shows trimethoprim—sulfamethoxazole resistanceational Society for Infectious Diseases.
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Table 1 Studies on antibiotic resistance in pneumococci
Period a Isolates (N) CTXM CFXN RIF IMP LEVO GRP GEMI MOXI CLA SXT
1993—963 143 2% 4%
1996 312 2.2%
1996 84 0% 0%
1997 68 0% 0% 9% 28%
1996—98 4 80 6.25%
1997—2000 101 0% 0%
1997—2000 42 0% 0% 0%
1997—2000 21 0% 0% 81%
1999—2001 5 83 0% 0% 0% 0%
1999—2000 6 142 2.3% 0% 90%
1999—2001 51 1.96% 37.2%
1999—2001 212 2.3% 2.1% 2.3%
2000—2001 10 85 0% 46%
2001 40 0% 0% 40%
2002 43 3.6% 44%
CTXM: cefotaxime; CFXN: ceftriaxone; RIF: rifampin; IMP: imipenem; LEVO: levofloxacin; GRP: grepafloxacin; GEMI: gemifloxacin; MOXI:
moxifloxacin; CLA: chloramphenicol; SXT: trimethoprim—sulfamethoxazole.
a References not cited here can be found online — see Appendix A.rates up to 50%,6,10 i.e., it should not be used as an empirical
option in probable pneumococcal meningitis.
Continued surveillance of antibiotic resistance patterns in
general and particularly in third generation cephalosporins
are key strategies in Turkey for the treatment of pneumo-
coccal meningitis.
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Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.ijid.2005.03.009.
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